Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats

• DOI: 10.1152/ajpgi.00420.2004
• Publication Date: 2004-12-24T02:27:45Z
• Authors: Hitoshi Yoshiji; Ryuichi Noguchi; Shigeki Kuriyama; Yasuhide Ikenaka; Junichi Yoshii; Koji Yanase; Tadashi Namisaki; Mitsuteru Kitade; Tsutomu Masaki; Hiroshi Fukui
• Keywords: Imatinib Mesylate

It is widely recognized that activated hepatic stellate cells (HSC) play a pivotal role in development of liver fibrosis. A platelet-derived growth factor (PDGF) the most potent mitogen for HSC. The aim this study was to examine effect imatinib mesylate (STI-571, Gleevec), clinically used PDGF receptor (PDGFR) tyrosine kinase inhibitor, on experimental rat model pig serum-induced fibrosis assess daily oral administration STI-571 indexes markedly attenuated and hydroxyproline serum markers. number alpha-smooth muscle actin-positive mRNA expression alpha2-(I)-procollagen, tissue inhibitor metalloproteinases-1, transforming factor-beta were also significantly suppressed by STI-571. Our vitro showed PDGF-BB-induced proliferation migration alpha-SMA alpha2-(I)-procollagen HSC dose-dependent manner. phosphorylation PDGFR-beta, MEK1/2, Akt Because clinical practice, it may provide an effective new strategy antifibrosis therapy.